Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: Tachyphylaxis after theophylline therapy

Giustina, Thomas A.; Chan, Sai C.; Thiel, Marcella L.; Baker, James; Hanifin, Jon M.

doi:10.1016/0091-6749(84)90254-9

Cited by 34 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed there is evidence to suggest that cyclic AMP hydrolytic activity is increased in mononuclear leukocytes from patients with atopic disease (Grewe et al, 1982) which has been attributed to an elevated cyclic AMP specific PDE activity (Butler et al, 1983; Bridsh Joumal of Pharmacology (1995) 116, 3169-3174 -rliferation Holden et al, 1986;Sawai et al, 1995). Moreover the more active cyclic AMP-PDE isoform in atopic leukocytes has been demonstrated to have a greater sensitivity to inhibition by the type IV PDE inhibitor, RO 20-1724 than the PDE in normal leukocytes (Giustina et al, 1984).…”

Section: Introductionmentioning

confidence: 99%

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis

Banner

Roberts

Page

1995

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis

Banner

Roberts

Page

1995

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Older inhibitors of phosphodiesterases, such as aminophylline and papaverine, have been tried in atopic eczema, but have not reached clinical use. [39] However, newer and more effective inhibitors of phosphodiesterase for topical use are under development and have shown promising results in adults. [40] …”

Section: Phosphodiesterase Inhibitorsmentioning

confidence: 99%

Treatment of Childhood Eczema

Granlund

2002

Pediatric Drugs

View full text Add to dashboard Cite

Eczema in childhood is almost always atopic eczema, a common disease with huge impact on the quality of life of the child and family. Although atopic eczema constitutes part of the atopic syndrome, avoidance of allergens is never enough for disease control. Treatment of eczema in childhood has the same components as in adults. Emollients constitute the preventive background therapy in all stages of eczema, and topical corticosteroids are still the mainstay of treatment. Infectious exacerbation may require the use of a short course of topical or systemic antimicrobials. UV phototherapy should be considered as an adjunctive treatment to assist topical corticosteroids after an acute exacerbation of the disease. Cyclosporine can also be used in the treatment of childhood eczema in severe cases. Maternal allergen avoidance for disease prevention, oral antihistamines, Chinese herbs, dietary restriction in established atopic eczema, homeopathy, house-dust mite reduction, massage therapy, hypnotherapy, evening primrose oil, emollients, and topical coal tar are other temporarily used treatment modalities, without, however, firm evidence of efficacy from proper controlled trials. Calcineurin inhibitors constitute a new generation of drugs for both adult and childhood eczema already marketed in some countries. It is postulated that they will replace topical corticosteroids as first-line treatment of eczema.

show abstract

“…Perhaps the most therapeutically significant feature of this atopic isoenzyme is its much greater sensitivity to a variety of PDE inhibitors (20). This aspect is already being utilized in clinical trials of topical PDE-inhibitors for AD, as will be discussed below.…”

Section: Monocyte Influence On T Cellsmentioning

confidence: 99%